Black Rock Inc. Graybug Vision, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.76 - $1.25 $24,237 - $39,863	-31,891 Reduced 98.03%	642 $1,000
Q1 2022 May 12, 2022	SELL	$1.13 - $1.93 $1,759 - $3,005	-1,557 Reduced 4.57%	32,533 $40,000
Q4 2021 Feb 10, 2022	BUY	$1.74 - $3.6 $1,505 - $3,114	865 Added 2.6%	34,090 $63,000
Q3 2021 Nov 09, 2021	SELL	$3.18 - $5.17 $2,200 - $3,577	-692 Reduced 2.04%	33,225 $110,000
Q2 2021 Aug 11, 2021	BUY	$3.53 - $6.1 $119,727 - $206,893	33,917 New	33,917 $184,000

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.